Clinical trial
Study to Compare How the Body Changes the Blood Level of Darifenacin Tablet Form…
NCT00413426 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00413426 |
|---|---|
| Title | Study to Compare How the Body Changes the Blood Level of Darifenacin Tablet Form vs. the Modified Release Liquid Form in Healthy Subjects |
| Official title | An Open-labeled, Randomized, Single Dose, Three Period, 2-sequence Crossover Study to Investigate the Pharmacokinetics of Darifenacin When Given as 7.5 mg Oral Doses of a Modified Release Suspension, as Compared to the Commercial Modified Release Tablet in Healthy Adult |
| Lead sponsor | Novartis, Industry |
| Collaborators | Procter and Gamble Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Healthy |
| Intervention type | Drug |
| Interventions | Darifenacin (DAR328) |
| Enrollment | 28 |
| Start date | Jun 1, 2006 |
| Completion | Sep 1, 2007 |
| First posted | Dec 19, 2006 |
| Last update posted | Apr 12, 2016 |
| Countries | India |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: